BOOST Pharma Will Present BT-101 Data in October
The clinical-stage firm will discuss its allogeneic stem cell therapy for osteogenesis imperfecta in Phoenix.
Updated on Sept. 24, 2026 in Biotech
Live Poll
Is now a good time to invest in early-stage medical companies ahead of final clinical trials?
On October 6, 2026, BOOST Pharma will present a clinical update on its investigative therapy BT-101 at the Cell & Gene Meeting on the Mesa in Phoenix. The presentation comes as the company prepares for a planned pivotal Phase III study for this rare bone condition.
Why it matters
The firm is using the industry event to showcase progress on BT-101, an off-the-shelf allogeneic stem cell therapy, as it seeks to address a condition with no currently approved FDA or EMA treatments. This development marks a significant step toward potential Phase III trial initiation.
In the Phase I/II BOOSTB4 study, the BT-101 therapy demonstrated a 70% reduction in fracture rates compared to the natural history of the condition. Osteogenesis imperfecta, which results in brittle bones, affects an estimated 1 in 15,000 people globally.
The players
BOOST Pharma
A clinical-stage biopharmaceutical company focused on developing allogeneic stem cell therapies.
Hans Schambye
The CEO of BOOST Pharma who is leading the company through its Phase III development strategy.
The details
BT-101 is an allogeneic stem cell therapy, meaning it uses donor cells rather than cells from the patient's own body to treat the underlying cause of brittle bones. The therapy has been granted Orphan Drug Designation in both the U.S. and Europe, a regulatory status provided to drugs intended to treat rare medical conditions. The company is now leveraging these findings to engage with investors ahead of a formal entry into Phase III testing.
Timeline
October 4, 2026: CEO Hans Schambye attends the Alliance for Regenerative Medicine CEO Summit.
October 5-7, 2026: The Cell & Gene Meeting on the Mesa takes place in Phoenix.
October 6, 2026: Hans Schambye presents the BT-101 program update at the Arizona Biltmore Hotel.
The Tech Race
The Cell & Gene Meeting on the Mesa serves as a primary venue for regenerative medicine developers to present clinical results to the broader biotechnology investor community. BOOST Pharma is using its status as a 2026 Innovation Spotlight company at this event to signal its transition toward late-stage clinical development.
Because there are currently no FDA- or EMA-approved therapies for osteogenesis imperfecta, the progress of BT-101 represents a potential future treatment path for patients globally. Stakeholders should watch for clinical trial recruitment announcements following the October 2026 presentation.
The takeaway
BOOST Pharma is moving to capitalize on early clinical results as it positions itself for a pivotal Phase III study. Observers should track the upcoming presentation on October 6 for specific clinical protocol details and the company's anticipated timeline for Phase III trial launch.
Further reading
For more on the industry's latest clinical developments, visit Biotech.
More information
For more information on the company's research pipeline, visit the BOOST Pharma corporate website.
Source note: This article includes information reported by The Manila times.
Live Poll
Is now a good time to invest in early-stage medical companies ahead of final clinical trials?
